Chloé Barasinski
University of Auvergne
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Chloé Barasinski.
European Journal of Obstetrics & Gynecology and Reproductive Biology | 2015
Cécile Marie; Céline Sinoquet; Chloé Barasinski; D. Lemery; Françoise Vendittelli
OBJECTIVES The main aim of this article was to analyze short-term variation (STV) of the fetal heart rate according to maternal race. The secondary aim was to study the baseline fetal heart rate according to this factor. STUDY DESIGN This single-center historical cohort study covered the period from November 2008 through December 2011 (n=182). The inclusion criteria were: black women from sub-Saharan Africa or white European women, with a singleton pregnancy ≥34 weeks and fetal heart rate recorded by computerized analysis (Oxford Sonicaid System 8002) at a prenatal visit. The exclusion criteria were: medication likely to modify fetal heart rate, abnormal fetal heart rate tracing, and being in labor. A multiple linear regression analysis was used to study the association between maternal race and STV. RESULTS STV was lower by 2.6ms in fetuses of black women (n=55) compared to those of white women (n=127) (8.9±2.1ms vs. 11.4±3.4ms) (p<0.001). The basal fetal heart rate was higher (p=0.001), and the recording criteria were met less often for the black women (p=0.04). After adjustment for maternal age, body mass index at the beginning of pregnancy, maternal cigarette smoking, parity, gestational diabetes, gestational age at the time of the fetal heart rate recording, and the time between the last meal and the recording, mean STV was lower by 3.1±0.6ms in fetuses of black compared with white women (p<0.001). CONCLUSION STV is lower in fetuses of black women compared to those of white women in a low-risk population. A study of black and white women with high-risk pregnancies is necessary to assess the impact of medical practices on perinatal outcome after STV analysis.
BMJ Open | 2016
Chloé Barasinski; Françoise Vendittelli
Introduction The scientific data currently available do not allow any definitive conclusion to be reached about what type of pushing should be recommended to women during the second stage of labour. The objective of this trial is to assess and compare the effectiveness of directed open-glottis pushing versus directed closed-glottis pushing. Secondary objectives are to assess, according to the type of pushing: immediate maternal and neonatal morbidity, intermediate-term maternal pelvic floor morbidity, uncomplicated birth, and womens satisfaction at 4 weeks post partum. Methods and analysis This multicentre randomised clinical trial compares directed closed-glottis pushing (Valsalva) versus directed open-glottis pushing during the second stage of labour in 4 hospitals of France. The study population includes pregnant women who received instruction in both types of pushing, have no previous caesarean delivery, are at term and have a vaginal delivery planned. Randomisation takes place during labour once cervical dilation ≥7 cm. The principal end point is assessed by a composite criterion: spontaneous delivery without perineal lesion (no episiotomy or spontaneous second-degree, third-degree or fourth-degree lacerations). We will need to recruit 125 women per group. The primary analysis will be by intention-to-treat analysis, with the principal results reported as crude relative risks (RRs) with their 95% CIs. A multivariate analysis will be performed to take prognostic and confounding factors into account to obtain adjusted RRs. Ethics and dissemination This study was approved by a French Institutional Review Board (Comité de Protection des Personnes Sud Est 6:N°AU1168). Results will be reported in peer-reviewed journals and at scientific meetings. This study will make it possible to assess the effectiveness of 2 types of directed pushing used in French practice and to assess their potential maternal, fetal and neonatal effects. Findings from the study will be useful for counselling pregnant women before and during labour. Trial registration number Agence national de sécurité du médicament et des produits de santé (ANSM): 150099B-22 and IDRCB: 2014-A01920-47. ClinicalTrials.gov: NCT02474745. Pre-result stage.
Gynécologie Obstétrique Fertilité & Sénologie | 2017
Corinne Dupont; M. Carayol; C. Le Ray; Chloé Barasinski; R. Beranger; A. Burguet; A. Chantry; C. Chiesa; Bénédicte Coulm; Anne Evrard; C. Fischer; L. Gaucher; C. Guillou; F. Leroy; E. Phan; A. Rousseau; Véronique Tessier; Françoise Vendittelli; Catherine Deneux-Tharaux; Didier Riethmuller
OBJECTIVES To define the different stages of spontaneous labour. To determine the indications, modalities of use and the effects of administering synthetic oxytocin. And to describe undesirable maternal and perinatal outcomes associated with the use of synthetic oxytocin. METHOD A systematic review was carried out by searching Medline database and websites of obstetrics learned societies until March 2016. RESULTS The 1st stage of labor is divided in a latence phase and an active phase, which switch at 5cm of cervical dilatation. Rate of cervical dilatation is considered as abnormal below 1cm per 4hour during the first part of the active phase, and below 1cm per 2hours above 7cm of dilatation. During the latent phase of the first stage of labor, i.e. before 5cm of cervical dilatation, it is recommended that an amniotomy not be performed routinely and not to use oxytocin systematically. It is not recommended to expect the active phase of labor to start the epidural analgesia if patient requires it. If early epidural analgesia was performed, the administration of oxytocin must not be systematic. If dystocia during the active phase, an amniotomy is recommended in first-line treatment. In the absence of an improvement within an hour, oxytocin should be administrated. However, in the case of an extension of the second stage beyond 2hours, it is recommended to administer oxytocin to correct a lack of progress of the presentation. If dynamic dystocia, it is recommended to start initial doses of oxytocin at 2mUI/min, to respect at least 30min intervals between increases in oxytocin doses delivered, and to increase oxytocin doses by 2mUI/min intervals without surpassing a maximum IV flow rate of 20mUI/min. The reported maternal adverse effects concern uterine hyperstimulation, uterine rupture and post-partum haemorrhage, and those of neonatal adverse effects concern foetal heart rate anomalies associated with uterine hyperstimulation, neonatal morbidity and mortality, neonatal jaundice, weak suck/poor breastfeeding latch and autism. CONCLUSION The widespread use of oxytocin during spontaneous labour must not be considered as simply another inoffensive prescription without any possible deleterious consequences for mother or foetus. Conditions for administering the oxytocin must therefore respect medical protocols. Indications and patient consent have to be report in the medical file.
European Journal of Obstetrics & Gynecology and Reproductive Biology | 2016
Françoise Vendittelli; Chloé Barasinski; Bruno Pereira; M. Dreyfus; D. Lemery; Marie-Hélène Bouvier-Colle
OBJECTIVE The principal objective of this study was to describe the policies reported by French maternity units for the prevention and early management of postpartum haemorrhage (PPH). The second objective was to assess their variation according to hospital level and status. STUDY DESIGN Cross-sectional observational study of French maternity units, from January 2010 to April 2011. The medical supervisor (obstetrician or midwife) of participating maternity wards completed a questionnaire designed to ascertain the units protocol for preventing and managing PPH after both vaginal and caesarean deliveries at a gestational age >22 weeks (or a birth weight >500g). The main outcome measure was the percentage of units reporting protocols adhering to the principal criteria for adequate management defined by the 2004 French guidelines for PPH. RESULTS 252 maternity units participated in the survey. Almost all units had a written protocol for PPH (97.2%). For vaginal deliveries, 82.5% of units had a definition of PPH (>500ml) and 92.8% had a policy of preventive oxytocin use. For caesareans, only 23.8% defined PPH (as >1000ml), 68.8% used manual delivery of the placenta, and 76.9% recommended oxytocin injection immediately after the birth. The first-line medication for PPH was oxytocin (96.3%) and the second-line treatment a prostaglandin (97.5%). Level III maternity units had a definition of haemorrhage for vaginal deliveries more often than did other levels of care (P=0.04). Manual removal of the placenta after caesareans was significantly more frequent in level I than level III units (P=0.008) and in private than other types of maternity units. Medical management of haemorrhage did not differ according to level of care or maternity status. CONCLUSIONS The responses by maternity unit supervisors showed significant improvement in the management of PPH accordingly to the 2004 French guidelines, especially for the third stage of labour. This improvement did not differ between hospitals by levels of care or legal status.
BMC Pregnancy and Childbirth | 2016
Françoise Vendittelli; Chloé Barasinski; Bruno Pereira; D. Lemery
EBCOG’s 26th European Congress of Obstetrics and Gynaecology | 2018
Chloé Barasinski; Anne Debost-Legrand; D. Lemery; Françoise Vendittelli
EBCOG’s 26th European Congress of Obstetrics and Gynaecology | 2018
Chloé Barasinski; Anne Debost-Legrand; D. Lemery; Françoise Vendittelli
16èmes journées du Collège National des Sages-Femmes de France | 2018
Chloé Barasinski; Anne Debost-Legrand; D. Lemery; Françoise Vendittelli
Revue de médecine périnatale | 2017
Corinne Dupont; M. Carayol; C. Le Ray; Chloé Barasinski; R. Beranger; A. Burguet; A. Chantry; C. Chiesa; Bénédicte Coulm; Anne Evrard; C. Fischer; Laurent Gaucher; C. Guillou; F. Leroy; Emmanuelle Phan; A. Rousseau; Véronique Tessier; Françoise Vendittelli; Catherine Deneux-Tharaux; Didier Riethmuller
31st International Confederation of Midwives (ICM) trienal congress | 2017
Corinne Dupont; Didier Riethmuller; Catherine Deneux-Tharaux; Rémi Beranger; Anne Chantry; Laurent Gaucher; Camille Le Ray; Chloé Barasinski; Françoise Vendittelli; Bénédicte Coulm; Véronique Tessier; A. Rousseau; A. Burguet; Catherine Fischer; Camille Guillou; Fabienne Leroy; Coralie Chiesa-Dubruille; Emmanelle Phan; Anne Evrard; M. Carayol